Breast Cancer

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

By

Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

By

The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

By

With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

By

It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

By

Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

By

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

By

Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Computer analysis is not better than human clinical evaluation when it comes to measuring breast density

In the United States, the standard for monitoring breast density is through the Breast Imaging Reporting and Data System (BI-RADS). There has been recent concern regarding the reproducibility of this system, as there is subjectivity in the breast density estimated by radiologists.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

By

Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

By

Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.

New Methodology May Advance Precision Medicine

New Methodology May Advance Precision Medicine

By

A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.

The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

By

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Breast Cancer: Determining the Best Diet for Disease Prevention

Breast Cancer: Determining the Best Diet for Disease Prevention

By

Higher ERDP scores were significantly associated with developing breast cancer.

Hormone Therapy for Breast Cancer May Cause Diabetes

Hormone Therapy for Breast Cancer May Cause Diabetes

By

It was unknown whether breast cancer treatment plays a causal role in the onset of diabetes.

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

Post-Oophorectomy Estrogen Therapy May Not Increase Breast Cancer Risk in BRCA1 Carriers

By

It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.

Post-Surgery Accelerated Partial Breast Irradiation vs Whole-Breast Irradiation: QoL Outcomes

Post-Surgery Accelerated Partial Breast Irradiation vs Whole-Breast Irradiation: QoL Outcomes

By

A previous analysis showed that APBI had non-inferior efficacy.

Widening the Use of Preventive Therapies Against Breast Cancer

Widening the Use of Preventive Therapies Against Breast Cancer

By

Preventive treatments are strongly recommended in women with AH and LCIS.

HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

By

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

Olaparib May Not Improve Overall Survival vs Chemotherapy in Breast Cancer

By

At the time of final analysis, 192 of 302 patients had died.

Endocrine Therapy-Associated Alopecia Significantly Affects Quality of Life

Endocrine Therapy-Associated Alopecia Significantly Affects Quality of Life

By

Improvements in alopecia were, however, seen in 37 of 46 patients treated with topical minoxidil.

Identifying the Optimal Breast Cancer Screening Interval

Identifying the Optimal Breast Cancer Screening Interval

By

It is unclear whether breast cancer screening — and specifically mammography — reduces the likelihood of being diagnosed with advanced-stage disease.

Sarcopenia, Adiposity Significantly Associated With Mortality in Nonmetastatic Breast Cancer

Sarcopenia, Adiposity Significantly Associated With Mortality in Nonmetastatic Breast Cancer

By

Previous studies have demonstrated that sarcopenia, poor muscle quality, and excess adiposity are associated with higher mortality.

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

By

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

By

Phase 1 trials should be considered therapeutic options for some patients.

Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

By

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer

Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer

By

The median OS was not evaluable, though the estimated 2-year OS rate was 78.7%.

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

By

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs